ProKidney Corp - Class A — Liquidità Trimestrale (NASDAQ:PROK) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 441.07 M406.06 M372.13 M351.61 M335.57 M Totale passività 39.44 M36.08 M32.68 M33.27 M34.78 M Patrimonio netto totale -994.95 M-998.55 M-1 B-1.01 B-1.01 B Totale passività e patrimonio netto 441.07 M406.06 M372.13 M351.61 M335.57 M Debito totale ————— Indebitamento netto —————

Notizie

ProKidney nomina Greg Madison come chief commercial officer

BofA conferma rating Underperform su ProKidney con target a $1

Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK)

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:PROK) 2026-01-14

H.C. Wainwright avvia copertura su ProKidney con rating Buy e target di $12

H.C. Wainwright initiates ProKidney stock with Buy rating, $12 target

This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Compass Minerals Intl (NYSE:CMP), MYR Group (NASDAQ:MYRG)

ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy

ProKidney Corp. (PROK) Presents at Morgan Stanley 23rd Annual